What we got wrong about GLP-1s
4/10/202649 min
Search Engine is breaking its cowardly three-year silence on GLP-1s. We have been curious about them. We have been afraid of getting in trouble. We are no longer afraid. A conversation with Dr. Rachael Bedard about the many mistakes in how the media covered these drugs and what the research shows about their surprising effects. Dr. Bedard’s story on the rise of Ozempic Support the show! To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy Learn more about your ad choices. Visit https://podcastchoices.com/adchoices
Clips
Transcript preview
First 90 secondsPJ Vogt· Host0:00
[upbeat music] Okay, so here's something. Our show's motto: No question too big, no question too small. But there are some questions that I have on this show avoided. I'll give you an example. GLP-1s. [pensive music] Search engine has barely acknowledged their existence, which is fine, except I read a lot about them, I think a lot about them, and in my private life, I talk a lot about them. But when they cannonballed into American culture, I had a lot of questions that I didn't wanna ask in public. In twenty twenty-two and twenty twenty-three, GLP-1s were just, for me, too hot a topic. Going online felt like walking into a crazy shootout in an old Western saloon. Except instead of gunslingers, it was all fast draw scolders. There were scolders out there scolding celebrities for taking GLP-1s, but then they were getting scolded by other scolders for scolding celebrities. Some people got scolded because they were taking the drugs despite not being fat enough, scolded for wanting to lose fifteen pounds. Rich people, of course, were getting scolded all over the place, accused of ripping GLP-1s out of the hands of the people who actually needed them.